SCHEMBL4079989

SCHEMBL4079989

C=C(CCC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TET2 Q6N021 5/20 0.41
STING1 Q86WV6 1/20 0.35
CYP2D6 P10635 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
TSHR P16473 1/20 0.32
EPHX2 P34913 1/20 0.31
DGAT1 O75907 1/20 0.30
TET3 O43151 1/20 0.30
TET1 Q8NFU7 1/20 0.30
MEN1 O00255 1/20 0.30
GAA P10253 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4087831 0.88 EPHX2 (0.38) TET2STING1CYP2D6HDAC3HDAC1
SCHEMBL6380324 0.83 STING1 (0.35) STING1CYP2D6HDAC3HDAC1HDAC2
SCHEMBL18290180 0.83 STING1 (0.36) TET2STING1CYP2D6HDAC3HDAC1
SCHEMBL4084580 0.82 TET2 (0.37) TET2
SCHEMBL644646 0.82 TSHR (0.45) STING1CYP2D6HDAC3HDAC1HDAC2
SCHEMBL20851059 0.82 STING1 (0.34) STING1CYP2D6HDAC3HDAC1HDAC2
SCHEMBL4838871 0.81 TET2 (0.42) TET2CYP2D6HDAC3HDAC1HDAC2
SCHEMBL23161369 0.80 TSHR (0.39) TET2STING1CYP2D6HDAC3HDAC1
SCHEMBL28815438 0.78 STING1 (0.36) STING1CYP2D6HDAC3HDAC1HDAC2
SCHEMBL9218327 0.78 HDAC3 (0.35) TET2HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0841380-B1 Method of making polymeric binders and use thereof in antifouling paints WITCO GMBH (DE) 1999-08-25 EP claimed
EP-0841380-A1 Method of making polymeric binders and use thereof in antifouling paints Witco GmbH (DE) 1998-05-13 EP claimed
EP-4058435-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2022-09-21 EP disclosed
US-20220281819-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2022-09-08 US disclosed
CN-114728905-A Therapeutic compounds and methods of use 基因泰克公司 2022-07-08 CN disclosed
WO-2021097110-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2021-05-20 WO disclosed
WO-2021097110-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2021-05-20 WO disclosed
US-7494759-B2 Positive resist compositions and process for the formation of resist patterns with the same TOKYO OHKA KOGYO CO., LTD. (JP) 2009-02-24 US disclosed
US-20080070998-A1 Foam Production Method OJI PAPER CO., LTD. (JP) 2008-03-20 US disclosed
US-20070224538-A1 Positive Resist Compositions and Process for the Formation of Resist Patterns With the Same TOKYO OHKA KOGYO CO., LTD. (JP) 2007-09-27 US disclosed
EP-1795553-A1 PROCESS FOR PRODUCING FOAM Oji Paper Co., Ltd. (JP) 2007-06-13 EP disclosed
US-20030225230-A1 Polymers for antifouling coatings and a process for the preparation thereof JOTUN A/S 2003-12-04 US disclosed
EP-0841380-B1 Method of making polymeric binders and use thereof in antifouling paints WITCO GMBH (DE) 1999-08-25 EP disclosed
EP-0841380-A1 Method of making polymeric binders and use thereof in antifouling paints Witco GmbH (DE) 1998-05-13 EP disclosed
EP-0833870-A1 POLYMERS FOR ANTIFOULING COATINGS AND A PROCESS FOR THE PREPARATION THEREOF Jotun A/S (NO) 1998-04-08 EP disclosed
WO-1996041842-A1 POLYMERS FOR ANTIFOULING COATINGS AND A PROCESS FOR THE PREPARATION THEREOF JOTUN A/S (NO) 1996-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281819-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, NQO1, PCSK9 TET2 652/4885STING1 2192/4885CYP2D6 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.